Xaprila (xaliproden) / Sanofi - LARVOL DELTA

Machine learning-assisted prediction of PANoptosis-related molecular targets and precise screening of neuroprotective drugs for spinal cord injury. (PubMed, Exp Neurol) - "Through protein domain screening, it was verified via proof-by-contradiction assays that the drug Xaliproden can establish robust interactions with the 7XMK, 7FCZ and 7FD0 domains of Ripk1, a core molecule of the PANoptosome, via a network of multiple hydrogen bonds. This finding provides a novel screening strategy for neuroprotective drugs for spinal cord injury and is of great significance for promoting the establishment of a precision treatment system for the acute phase of injury."

Journal • CNS Disorders • Orthopedics • AURKA • MCM5 • MCM6 • RIPK1 • TACC3

Xaliproden improves diabetic kidney disease through JNK-mediated renal tubular protection. (PubMed, Biochem Pharmacol) - "These effects were mediated through downregulation of the c-Jun N-terminal kinase/p65/c-Jun signaling pathway. In conclusion, these findings demonstrate that xaliproden confers reno-protective effects by mitigating renal tubular epithelial cell damage and improving renal function in DKD, suggesting its potential as a therapeutic option for DKD."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Oncology • Renal Disease • CASP3 • IL6 • MAPK8 • SMAD2 • TNFA

Informatics Approach Towards Targeting HTR1B Pathways in Neuropharmacology for Migraine Treatment. (PubMed, Curr Neuropharmacol) - "This study provides a foundation for targeted HTR1B-based migraine therapies and highlights the value of informatics tools in accelerating drug discovery in neuropharmacology."

Journal • CNS Disorders • Migraine • Pain

The Xaliproden Nanoscale Zirconium-Porphyrin Metal-Organic Framework (XAL-NPMOF) Promotes Photoreceptor Regeneration Following Oxidative and Inflammatory Insults. (PubMed, Int J Nanomedicine) - "As an amplifier, NPMOF can enhance the anti-inflammatory efficacy and neuroprotective effect of xaliproden. XAL-NPMOF could be a novel and convenient option for the treatment of AMD."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders

Repurposing Drugs for Treatment of Age-Related Macular Degeneration. (PubMed, Adv Exp Med Biol) - "This short review summarizes progress in several classes of drugs considered for repurposing: GPR-143 agonists (L-DOPA), anti-diabetic drugs (metformin, acarbose, empagliflozin, fenofibrate), mitochondrial activators (PU-91), and serotonin pathway drugs (fluoxetine, flibanserin, xaliproden, buspirone). The promises and caveats of repurposing are discussed herein."

Journal • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • GPR143

The Selective 5-HT1A Agonist SR57746A Protects Intestinal Epithelial Cells and Enteric Glia Cells and Promotes Mucosal Recovery in Experimental Colitis. (PubMed, Inflamm Bowel Dis) - "Treatment with SR57746A prevents inflammatory cell damage and apoptosis in IECs and EGCs, similar to the neurotrophic effects of EGCs on IECs. Topical treatment with SR57746A could be a candidate for clinical evaluation in the treatment of IBD."

Journal • Colorectal Cancer • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Oncology • Solid Tumor • CD4